London – A dengue fever pill manufactured by Johnson & Johnson appeared to protect against a version of the virus in a few patients, in a tiny human challenge trial conducted in the United States. Before presenting the research at the American Society of Tropical Medicine and Hygiene Annual Meeting in Chicago, the company noted that there are presently no …
PENNSYLVANIA – The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive topline results from its Phase 2b FRONTIER 1 clinical trial evaluating the novel, first and only oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis (PsO).1 The trial achieved all primary and secondary efficacy endpoints. A greater proportion of patients who received JNJ-2113 achieved …
London – Application is supported by data from the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival (PFS) CARTITUDE-4 is the first randomized Phase 3 study investigating the efficacy of a cell therapy as early as after first relapse in multiple myeloma RARITAN, N.J., June 6, 2023 – The Janssen Pharmaceutical Companies of Johnson …
